YR0133
Human LAG-3 Monoclonal Antibody
Size
£355.00
- SKU:
- YR0133
- Additional Names:
- CD223
- Application:
- ELISA, FuncS, Neutralisation
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- Abclonal
- Immunogen:
- Human LAG-3
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- P18627
- Synonyms:
- CD223;EMT;homolog of mouse T-cell itk/tsk;IL-2-inducible T-cell kinase;interleukin-2-inducible T-cell kinase;kinase EMT;LPFS1;LYK;lymphocyte activation gene 3 protein;lymphocyte-activation gene 3;Protein FDC;PSCTK2;T-cell-specific kinase;tyrosine-protein kinase ITK/TSK;tyrosine-protein kinase LYK
- Extra Details:
- Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3-blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer.Relatlimab and the anti-PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti-PD-1 monotherapy.
- Shipping Conditions:
- Blue Ice